VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study

Accriva Diagnostics

Status

Completed

Conditions

Platelet Aggregation

Coronary Disease

Treatments

Diagnostic Test: VerifyNow PRUTest

Study type

Observational

Funder types

Industry

Identifiers

NCT04492423

VFN-CSS-16-0003

Details and patient eligibility

About

The purpose of this study is to determine the range of expected PRUTest values in patients in the intended use population receiving dual antiplatelet treatment with aspirin and prasugrel (Effient®), or ticagrelor (Brilinta®).

Full description

The on-drug reference range study will be performed by measuring venous blood samples in duplicate collected from patients receiving prasugrel (Effient®), or ticagrelor (Brilinta®). Subjects must be on aspirin at the doses prescribed by their treating physician.

When possible, venous blood samples may be collected in conjunction with routine laboratory testing, to minimize the number of needle sticks for the subject. Alternatively, samples may be collected separately to complete the study.

A CBC measurement must be performed for each enrolled subject from a sample collected at the time of blood draw or within ± one week and tested at a certified laboratory. Samples for PRUTest collected in conjunction with a CBC must be drawn after the PRUTest sample.

Up to 130 subjects will be enrolled in the study to facilitate collection of the minimum number of blood samples needed to determine the on-drug reference range of prasugrel (Effient®), or ticagrelor (Brilinta®).

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

• Males and females 18 years and older
- Able and willing to provide written informed consent.
- Current treatment with aspirin (any dose).
- Have a planned or scheduled percutaneous coronary intervention (PCI) with the potential to receive treatment with prasugrel (Effient®), or ticagrelor (Brilinta®) following an oral loading dose or on maintenance treatment for a minimum of seven days who may have symptomatic cerebrovascular disease (transient ischemic attack or following a thrombotic stroke) or cardiovascular disease.

Exclusion criteria

• Unable to provide written informed consent.
- Currently receiving an investigational antiplatelet agent.
- GP IIb/IIIa therapy (ReoPro®, Integrilin®, Aggrastat®) within the past 2 weeks.
- Received any therapy containing dipyridamole (Persantine®, Aggrenox®) within the past 2 weeks.
- Women who may be pregnant or are of child bearing potential